Liar. I've never [even now] been asked such a thing, or at least not in a civil manner.
If anyone cares, I have a small position in MYRX which I got as a result of the spinoff. I was originally interested in MYGN because it was priced as if the drug discovery business had zero or negative value, and I like drug discovery businesses (I'm an organic chemist with a lot of life sciences contact, so I'm reasonably good at weeding out no-chance programs...well, except that some biologics that I never would have believed are reaching the market. But I still have a good nose for small molecule projects). Part of the discipline is having a bunch of small positions and waiting for actual developments before expanding them; my small position is typical for investing in a company that has not completed a registration trial.
There is a population on this board of people who have no interest in or feel for drug discovery companies. I have no clue why such people would invest in one, or why they stay around.
It was observed a while ago that Roche is doing a nice business with Avastin against GBM. The combination of Carboplatin and Azixa did just as well against GBM as Avastin does. That won't go forward, because Carboplatin alone was a flop. Azixa is a very promising drug, and I'm sticking around to see what it can do. I've shown my work previously on this board: MYRX is now priced as if Azixa will become either/or with Avastin. It will probably become part of the arsenal of drugs for treating first recurrences of many cancers, which would justify a MYRX price on the order of $30. There is a biochemical argument why Azixa could be very broadly useful in cancer treatment--if true, that would support an implausibly high stock price. I'm here for an even chance of a $30 stock price [and a small chance of more], and I'm not interested at all in liquidation at $8.
I strongly recommend to the self-named Brilliant... and his ilk that they get out of MYRX and invest in a basket of below-NAV closed end funds. It gives an admirable return with very low risk...and no excitement at all.